Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:16:42 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



News for U:RNAZ from 2024-07-19 to 2025-07-18 - 30 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-05-28 08:00U:RNAZNews ReleaseTransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
2025-05-08 08:05U:RNAZNews ReleaseTransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
2025-05-05 17:00U:RNAZNews ReleaseTransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
2025-05-02 16:10U:RNAZNews ReleaseTransCode Therapeutics Announces 1-for-28 Reverse Stock Split
2025-05-01 09:01U:RNAZNews ReleaseTransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
2025-04-21 16:30U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
2025-03-27 16:37U:RNAZNews ReleaseTransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
2025-03-25 18:24U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
2025-03-23 23:11U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-03-13 07:47U:RNAZNews ReleaseTransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
2025-02-25 16:15U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Results of Special Meeting
2025-02-06 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
2025-02-04 16:15U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
2025-01-14 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
2025-01-07 08:00U:RNAZNews ReleaseNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
2024-12-18 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
2024-11-29 16:25U:RNAZNews ReleaseTransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
2024-11-27 07:00U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces $8 Million Private Placement
2024-11-25 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces 1-for-33 Reverse Stock Split
2024-11-12 07:00U:RNAZNews ReleaseTransCode Therapeutics Open Letter to Shareholders
2024-11-05 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
2024-10-23 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
2024-10-10 07:00U:RNAZNews ReleaseTransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
2024-09-17 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
2024-09-10 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer
2024-09-05 07:00U:RNAZNews ReleaseTransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
2024-08-15 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
2024-07-24 16:05U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Closing of Public Offering
2024-07-22 22:30U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Pricing of Public Offering
2024-07-22 16:07U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock